BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $16.42 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 1.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 421,121 shares of the biopharmaceutical company’s stock after acquiring an additional 4,385 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned 0.56% of Xenon Pharmaceuticals worth $16,419,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in XENE. Wellington Management Group LLP boosted its holdings in Xenon Pharmaceuticals by 140.9% during the fourth quarter. Wellington Management Group LLP now owns 4,162,654 shares of the biopharmaceutical company’s stock worth $191,732,000 after purchasing an additional 2,434,546 shares during the last quarter. First Light Asset Management LLC boosted its stake in shares of Xenon Pharmaceuticals by 173.3% during the 4th quarter. First Light Asset Management LLC now owns 1,645,490 shares of the biopharmaceutical company’s stock worth $75,791,000 after buying an additional 1,043,420 shares during the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of Xenon Pharmaceuticals by 15.6% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,666,666 shares of the biopharmaceutical company’s stock valued at $261,007,000 after acquiring an additional 766,666 shares in the last quarter. First Turn Management LLC acquired a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at about $31,339,000. Finally, Avidity Partners Management LP raised its holdings in Xenon Pharmaceuticals by 153.9% during the fourth quarter. Avidity Partners Management LP now owns 815,993 shares of the biopharmaceutical company’s stock worth $37,585,000 after acquiring an additional 494,593 shares in the last quarter. 95.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on XENE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price target on shares of Xenon Pharmaceuticals in a research report on Friday, August 9th. Royal Bank of Canada restated an “outperform” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, June 18th. Wedbush cut their price target on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an “outperform” rating for the company in a research note on Friday, August 9th. Needham & Company LLC lowered their price objective on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Finally, Citigroup cut their target price on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a “buy” rating for the company in a research note on Friday, May 10th. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $58.78.

Xenon Pharmaceuticals Trading Up 0.1 %

Shares of NASDAQ:XENE traded up $0.04 during trading on Friday, reaching $40.34. 229,795 shares of the stock were exchanged, compared to its average volume of 397,486. Xenon Pharmaceuticals Inc. has a 12 month low of $27.99 and a 12 month high of $50.99. The stock has a 50-day moving average price of $40.29 and a 200-day moving average price of $41.56. The firm has a market cap of $3.04 billion, a PE ratio of -14.89 and a beta of 1.26.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.05). During the same quarter in the previous year, the company posted ($0.72) earnings per share. On average, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -3.16 earnings per share for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.